SHAREHOLDER ALERT: Abraham, Fruchter & Twersky, LLP Announces An Investigation of Sarepta Therapeutics, Inc. (SRPT)

Abraham, Fruchter & Twersky, LLP (“AF&T”) is investigating claims on behalf of investors who purchased Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ:SRPT) common stock.

Sarepta is currently seeking accelerated approval of its drug eteplirsen from the Food and Drug Administration (“FDA”). On January 15th, the FDA published a document concerning Sarepta’s pending drug application stating that “we cannot approve drugs for which substantial evidence of effectiveness has not been established.” That same day, in reaction to the FDA’s negative views, Sarepta’s stock opened at $15.00 per share, a more than 50% drop from the previous day’s closing price of $31.63 per share.

If you would like to discuss AF&T’s investigation into potential claims relating to Sarepta, or if you have any questions concerning your rights as a potential lead plaintiff, you may contact: Jeffrey S. Abraham or Philip T. Taylor of AF&T toll free at (800) 440-8986, or via e-mail at jabraham@aftlaw.com or ptaylor@aftlaw.com.

AF&T, which is based in New York with an office in California, has extensive experience in shareholder and securities class action cases, and the firm has been ranked among the leading class action law firms in terms of recoveries achieved by a survey of class action law firms conducted by Institutional Shareholder Services.

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160115005859/en/